CBS 2019
CBSMD教育中心
中 文

Scientific Library

Abstract

Recommended Article

Evaluation and Management of Right-Sided Heart Failure: A Scientific Statement From the American Heart Association Surgical ineligibility and mortality among patients with unprotected left main or multivessel coronary artery disease undergoing percutaneous coronary intervention Effect of Empagliflozin on Cardiovascular and Renal Outcomes in Patients With Heart Failure by Baseline Diabetes Status - Results from the EMPEROR-Reduced Trial Clinical Significance of Concordance or Discordance Between Fractional Flow Reserve and Coronary Flow Reserve for Coronary Physiological Indices, Microvascular Resistance, and Prognosis After Elective Percutaneous Coronary Intervention Positive recommendation for angiotensin receptor/neprilysin inhibitor: First medication approval for heart failure without "reduced ejection fraction" Early Surgery or Conservative Care for Asymptomatic Aortic Stenosis Dapagliflozin for treating chronic heart failure with reduced ejection fraction INTERMACS Profiles and Outcomes Among Non–Inotrope-Dependent Outpatients With Heart Failure and Reduced Ejection Fraction

Review Article2017 Nov;5(11):763-771.

JOURNAL:JACC Heart Fail. Article Link

Heart Failure With Mid-Range (Borderline) Ejection Fraction: Clinical Implications and Future Directions

Hsu JJ, Ziaeian B, Fonarow GC. Keywords: HFbEF; HFmrEF; HFpEF; epidemiology; heart failure with borderline ejection fraction; heart failure with mid-range ejection fraction; heart failure with preserved ejection fraction; outcomes

FULL TEXT PDF